NCT04646044 - A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 13, 2020

Primary Completion Date

May 11, 2021

Study Completion Date

May 18, 2021

Conditions

Covid-19Coronavirus Disease 2019

Interventions

DRUG

Bempegaldesleukin

Administered as an intravenous infusion

DRUG

Standard of Care

Standard of Care Treatment for COVID-19 Infection

OTHER

Placebo

Administered as an intravenous infusion

Trial Locations (4)

Clinical Site Partners - Winter Park - HyperCore -PPDS, Winter Park

A G A Clinical Trials - HyperCore - PPDS, Hialeah

New Generation Medical Research, Hialeah

SMS Clinical Research, LLC, Mesquite